Breaking News

Novo Nordisk to Acquire Ocedurenone from KBP Biosciences

Ocedurenone is currently being evaluated in a phase 3 trial in uncontrolled hypertension with potential in cardiovascular and kidney disease.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Novo Nordisk has entered an agreement to acquire ocedurenone for uncontrolled hypertension with potential application in cardiovascular and kidney disease from KBP Biosciences, for as much as $1.3 billion.   Ocedurenone is an orally administered, small molecule, non-steroidal mineralocorticoid receptor antagonist (nsMRA) that is currently being evaluated in the phase 3 trial CLARION-CKD in uncontrolled hypertension and advanced chronic kidney disease (CKD).    To date, ocedurenone has been i...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters